Estrella Immunopharma, Inc.ESLA
Price (close)
$0.47
Market cap
$20.3M
P/E
—
Revenue (TTM)
—
Net income
-$10.0M
Dividend yield
—
1-year total return
-59.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What Estrella Immunopharma, Inc. does.
company developing T-cell therapies to address treatment challenges for patients with cancers and autoimmune diseases. Our strategy is
to harness the evolutionary power of the human immune system to provide patients with potentially safer, more efficacious T-cell therapies
compared to traditional CAR-T therapies. Leveraging cutting-edge cellular engineering technologies, we aim to overcome the limitations
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | — | -$247,718 | -$996,104 | — | — | -$13.1M |
More on ESLA.
- Estrella Immunopharma, Inc. summary
- Estrella Immunopharma, Inc. financial statements
- Estrella Immunopharma, Inc. key metrics
- Estrella Immunopharma, Inc. health scores and style box
- Estrella Immunopharma, Inc. earnings
- Estrella Immunopharma, Inc. dividends
- Estrella Immunopharma, Inc. valuation
- Estrella Immunopharma, Inc. ownership and insiders
- Estrella Immunopharma, Inc. peers
Figures from Estrella Immunopharma, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.